Evaluating the efficacy and safety of single-agent etoposide intra-CSF chemotherapy in children and young people with relapsed/refractory central nervous system tumours
| العنوان: | Evaluating the efficacy and safety of single-agent etoposide intra-CSF chemotherapy in children and young people with relapsed/refractory central nervous system tumours |
|---|---|
| المؤلفون: | Butler, Anna, Meijer, Lisethe, Liu, Jo-Fen, Chohan, Manjit, Jalloh, Ibrahim, Macarthur, Donald, Parr, Margaret, Wilne, Sophie, Wilson, Shaun, Walker, David, Grundy, Richard, Dandapani, Madhumita |
| المساهمون: | Apollo - University of Cambridge Repository |
| المصدر: | Child's Nervous System. 39:1537-1544 |
| بيانات النشر: | Springer Science and Business Media LLC, 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Central nervous system tumours, Adult, Relpase, Adolescent, Progression-free survival, General Medicine, Blood braian barrier, Central Nervous System Neoplasms, Intra CSF etoposide, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Pediatrics, Perinatology and Child Health, Quality of Life, Chemotherapy, Humans, Neurology (clinical), Child, Etoposide |
| الوصف: | Purpose The aim of the project was to evaluate intra-CSF etoposide administration in a palliative setting for children and young people with relapsed/refractory central nervous system (CNS) tumours, with the primary endpoints being overall survival and progression-free survival time. A safety endpoint was to assess the side effect profile and complications of intra-CSF etoposide. Methods Thirty-five patients under the age of 30 years (median age: 5.33 years) were enrolled onto the project. The cross-centre study was a service evaluation, with a data collection spreadsheet designed in Nottingham and completed by both Nottingham and Oxford centres. Data was analysed using SPSS, assessing the overall survival and progression-free survival times, as well as the 6-month and 1-year survival rates. Results The median overall survival and progression-free survival times were 10.97 and 5.91 months, respectively. The 6-month and 1-year overall survival rates were 67% and 48%, and the progression-free survival rates were 50% and 22%. Age at the start of intra-CSF therapy was significantly associated with overall survival (P = 0.046), with the 6 + age group having improved overall survival. Treatment type was significantly associated with overall survival (P = 0.012), with etoposide intra-CSF treatment being associated with improved overall survival. Treatment duration was significantly associated with both overall survival (P P Conclusion Intra-CSF etoposide treatment has shown to increase both overall and progression-free survival significantly, whilst having few side effects and maintaining a good quality of life for patients, reflecting it as a beneficial therapy in the palliative setting. |
| وصف الملف: | application/pdf; text/xml |
| تدمد: | 1433-0350 0256-7040 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5543b8094e4f9e23d846226cf470166Test https://doi.org/10.1007/s00381-023-05872-wTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b5543b8094e4f9e23d846226cf470166 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14330350 02567040 |
|---|